Jeff Fischer

We've told you what we're looking for in our next investment. Now you tell us if we're on the right track.

The Drip Portfolio managers outline the six things they're looking for in their next high-growth investment.

We asked for names of high-growth companies. You responded with more than 50 potential investments.

The Drip Portfolio managers are looking for some excitement. Help them find a company with big growth potential.

The Drip Portfolio is up 80% since inception. Looks like buying Intel was a good idea after all.

With thousands of gene patent filings and strong management, this company definitely sounds like a Rule Breaker.

This year a small group of Fools visited the headquarters of a new paradigm drug company, Human Genome Sciences. Today that tour is summarized and the company is put through the first Rule Breaker criterion as we measure its top dog and first mover status in genomics-based biotech. With $8 billion in market value, there may be a great deal of long-term potential in HGS if it proves to be a Rule Breaker.

Campbell Soup has a few means to create value again, but the main one is to grow soup sales volume, which it has failed to do for three years. Other means (mergers, selling itself, new products) aren't likely to occur or be enough. The investment has changed enough that Drip Port is ready to replace it with something better. A new study will begin.

A Break Down analyzes a company's prospects based on our Rule Breaker criteria. We're spending the month Breaking Down several Rule Breaker candidates in search of a new purchase. Part two of our Break Down of Millennium Pharmaceuticals concludes that the company should be strongly considered.

The Rule Breaker's study of potential investments continues with a Break Down of biopharmaceutical leader Millennium Pharmaceuticals. The company is the top dog of genomics-focused biotechs when measured by market value, size and number of partnerships, and drug pipeline.

The Drip Port will begin to buy its additional shares of PepsiCo slowly and cautiously. This is partly due to lessons learned from Campbell Soup. With Campbell, the Drip Port rushed to buy shares at the start in order to balance the new position (based on dollars invested) with the port's older, much larger positions. Balancing of this nature may do more harm than good, however, as it did with Campbell Soup, because the

We're going to take a good, hard look at eight different companies this month to see who's worthy of Rule Breaker status.

After three years, the Drip Portfolio has grown to more than $6,000. Jeff Fischer reviews our strategy and asks for your Drip investing stories.

In announcing earnings today, Celera predicted doubled future sales and Starbucks added even more stores to its expansion plan.

We asked for your feedback, and we listened. Jeff Fischer explains what changes you'll see in future Drip Portfolio reports.

Several Rule Breakers will report their quarterly earnings this week. Will eBay have increased sales? Will Amazon reduce its operating losses? Stay tuned.

Three Drip Portfolio companies reported strong results this week. Also, an update on the cheapest and fastest way to start a Drip.

America Online answers concerns about advertising revenue and Celera considers creating its own drugs. Jeff Fischer reports.

The Drip Portfolio managers are ready to buy their first shares of Pepsi. Next question: What's the cheapest way to start a Drip?